The company is putting artificial intelligence to work in the hopes of coming up with more precise, effective tests and therapies for a range of diseases.
The technology, developed by life-sciences software firm Deep Lens, integrates cancer genetic data into an advanced platform to connect patients with studies and treatments.
A research team including MIT, Harvard and Stanford researchers has raised $20m in seed funding for their effort to map out immune cells with machine learning.
The federal agency continues to offer advice for healthcare and pharma industry professionals, and to take action against companies acting out of bounds.
The pharmaceutical analysis firm is continuing its contract analytical laboratory services running, with changes designed to keep people and products safe.
Over the past week, the agency has issued guidances, taken action to accelerate treatments and put a stop to fraudulent treatments for the pandemic-causing virus.
The purchase is aimed at expanding the company’s specialty diagnostics offerings in sample preparation technology, assay capabilities, bioinformatics and more.
Project ALS has selected Medidata’s biomarker discovery solution for its research projects, aiming to improve understanding of the ALS disease process and develop new therapeutic strategies.
Domainex is set to support Lunac’s discovery project for anticoagulant therapies with reduced bleeding risk, following the developer’s novel target validation.
Aiming to facilitate and accelerate discovery of biologics, Aridis’ Apex platform can also discover antibodies against viruses ‘within one day of a pandemic’.
Leveraging Eurofins’ pharmacology, in-vitro models and ADME capabilities, PharmaResources aims to accelerate drug discovery for its clients in small molecule drug R&D.
BioIVT taps into the advantages of hepatic cells for toxicology evaluations and screening studies, securing exclusive distribution agreement with upcyte.
Almirall enters drug discovery agreement with WuXi Biologics, gaining access to the WuXiBody platform to develop antibodies for the treatment of dermatological diseases.
Servier is set to support two research projects led by UCL to better understand the immune system’s collapse following infections from immune-inflammatory diseases.
Adaptate gains access to Iontas’ platform to select antibodies with optimal biophysical properties for the development of gamma delta T-cell modulating therapeutics.
After one year of collaborative work, Metrion and LifeArc agree to continue research on a joint project focused on neuroscience ion channel drug discovery for another year.
The modeling and simulation solutions provider Simulations Plus has been contracted to support countermeasure development for acute radiation syndrome in a partnership with a global pharma company.
